![]() |
市場調查報告書
商品編碼
1797974
2032 年寵物腸道微生物組檢測市場預測:按產品類型、寵物類型、樣本類型、應用、最終用戶和地區進行的全球分析Pet Gut Microbiome Testing Market Forecasts to 2032 - Global Analysis By Product Type, Pet Type, Sample Type, Application, End User and By Geography |
根據 Stratistics MRC 的數據,全球寵物腸道微生物組檢測市場預計在 2025 年達到 6,106 萬美元,預計到 2032 年將達到 1.736 億美元,預測期內的複合年成長率為 16.1%。
寵物腸道微生物組檢測是一種診斷過程,利用糞便樣本分析寵物消化道的微生物組成。此檢測可識別有益菌和有害菌,從而深入了解寵物的消化系統健康、免疫功能和潛在的飲食敏感性。透過評估微生物多樣性和平衡性,獸醫和飼主可以客製化營養和治療方案,以改善寵物的整體健康狀況。此檢測支持主動健康管理,及早發現腸道失衡和疾病徵兆,並促進寵物腸道功能達到最佳狀態。
據美國獸醫內科學院稱,研究人員分析了超過4000份寵物糞便樣本,以確定健康微生物組的核心。他們發現,大約28%的狗和13%的貓體內常見的大腸桿菌-志賀氏菌(包括大腸桿菌)含量升高,並且這些升高的水平與臨床症狀、胃腸道診斷和近期抗生素暴露顯著相關。
提高寵物的健康意識和人性化
隨著寵物越來越被視為家庭成員,飼主也開始投資預防保健和個人化營養。這種轉變推動了微生物組分析在檢測消化器官系統問題、過敏和免疫相關疾病的應用。寵物腸道微生物組檢測恰好滿足了這一需求,它提供了一種識別潛在健康問題(例如胃腸道問題和過敏)的方法,並在問題發展成慢性或嚴重疾病之前製定有針對性的干涉措施。整體獸醫護理和以健康為中心的寵物產品的興起,進一步推動了這個市場的擴張。
測試成本高且解釋複雜
雖然技術進步使得檢測更加經濟實惠,但它仍然是加值服務,並非所有飼主都能享受,尤其是飼主注重價格的寵物主人。此外,這些檢測產生的數據的複雜性也帶來了挑戰。結果通常包含大量的微生物種類及其相對豐度列表,這對於寵物飼主,甚至一些獸醫來說,都難以解讀並轉化為切實可行的建議。
直接面對消費者 (DTC) 模式和數位整合
DTC檢測套組可讓寵物飼主在家採集樣本,簡化流程並提升便利性。這種模式避免了去看獸醫的需要,提高了可及性和消費者參與度。透過將此類家用試劑套件與數位平台結合,公司可以為寵物飼主提供易於理解的報告、個人化的飲食建議以及聯繫營養專家的管道。這些技術的無縫整合不僅提升了用戶體驗,還創建了一個擴充性的經營模式,以覆蓋更廣泛的客戶群。
來自科學界和獸醫界的懷疑
由於擔心微生物組數據的臨床有效性、缺乏同行評審檢驗以及結果不一致,人們對此持謹慎態度。一些專家質疑缺乏堅實科學依據的微生物學介入措施的有效性。除非有嚴謹的研究和標準化方案的支持,否則這種懷疑態度可能會阻礙其融入主流獸醫學。由於缺乏對標準化方法和結果解釋的強力的科學共識,檢測公司可能難以在一個高度依賴專家建議的市場中獲得信譽並推動其廣泛應用。
新冠疫情對寵物腸道微生物組檢測市場產生了重大且正面的影響。在疫情封鎖期間,寵物擁有量大幅成長,這讓人們更加重視人與動物之間的紐帶,並推動了寵物健康和保健支出的成長。隨著飼主居家時間增加,對寵物健康的關注度也隨之增加,這種「寵物人性化」趨勢也隨之加速。疫情也凸顯了居家健康監測和診斷的價值,直接推動了對便捷的直銷型檢測套組的需求。
DNA定序套件市場預計將成為預測期內最大的市場
由於DNA定序套件盒技術提供卓越的準確性和全面的數據,預計在預測期內將佔據最大的市場佔有率。採用16S rRNA定序和散彈槍宏基因體學等技術的套件被認為是腸道微生物組分析的黃金標準,能夠深入了解寵物腸道中的細菌組成、多樣性和功能。這些先進的試劑套件對於診斷和研究都至關重要,因為它們能夠提供製定個人化治療方案和開發新型寵物保健產品所需的深入資訊。
預計診斷領域在預測期內將以最高的複合年成長率成長。
預計診斷領域將在預測期內實現最高成長率,這得益於對可操作健康洞察日益成長的需求。基於微生物組的診斷方法正被用於檢測寵物的胃腸道疾病、食物敏感性和免疫失衡。隨著人們日益意識到腸道健康對整體健康的影響,診斷工具也不斷發展,以提案針對性的治療方法。與人工智慧主導平台和個人化護理計畫的整合,正在強化微生物組診斷的價值提案。
預計亞太地區將在預測期內佔據最大的市場佔有率,這得益於寵物擁有量的成長、可支配收入的提高以及獸醫基礎設施的不斷擴張。中國、日本和印度等國家在寵物保健和健康產品上的支出正在增加。該地區人口技術嫻熟,數位健康解決方案的快速普及,正在推動微生物組檢測服務的需求。本地新興企業和全球企業正在投資客製化服務,以滿足多樣化的消費者需求。
由於都市化加快和寵物照護趨勢的演變,預計亞太地區將在預測期內實現最高的複合年成長率。該地區對預防性衛生和營養的認知日益提高,推動了先進診斷方法的採用。政府對生物技術創新的支持以及定序技術的日益普及,進一步促進了市場的成長。隨著寵物飼主尋求個人化和全面的護理,亞太地區已成為微生物組檢測創新和擴展的關鍵樞紐。
According to Stratistics MRC, the Global Pet Gut Microbiome Testing Market is accounted for $61.06 million in 2025 and is expected to reach $173.6 million by 2032 growing at a CAGR of 16.1% during the forecast period. Pet gut microbiome testing is a diagnostic process that analyzes the microbial composition within a pet's gastrointestinal tract using stool samples. This test identifies beneficial and harmful bacteria, offering insights into digestive health, immune function, and potential dietary sensitivities. By evaluating microbial diversity and balance, veterinarians and pet owners can tailor nutrition and treatment plans to improve overall wellness. It supports proactive health management, helping detect early signs of imbalance or disease and promoting optimal gut function in pets.
According to American College of Veterinary Internal Medicine, researchers analyzed over 4,000 fecal samples from pets to define a core healthy microbiome. They found that elevated levels of Escherichia-Shigella commonly including E. coli were present in approximately 28% of dogs and 13% of cats, and these elevations were significantly associated with clinical signs, gastrointestinal diagnoses, and recent antibiotic exposure
Growing pet health awareness & humanization of pets
As pets are increasingly viewed as family members, owners are investing in preventive care and personalized nutrition. This shift is encouraging the adoption of microbiome analysis to detect digestive issues, allergies, and immune-related conditions. Pet gut microbiome testing fits this need perfectly, as it offers a way to identify underlying health issues, such as gastrointestinal problems and allergies, and to develop targeted interventions before they become chronic and severe. The rise of holistic veterinary care and wellness-focused pet products further supports the expansion of this market.
High costs of testing & complexity of interpretation
While technological advancements have made the process more affordable, it remains a premium service that is not accessible to all pet owners, particularly those who are more price-sensitive. Furthermore, the complex nature of the data generated by these tests poses a challenge. The results, often including extensive lists of microbial species and their relative abundances, can be difficult for both pet owners and even some veterinarians to interpret and translate into actionable advice.
Direct-to-consumer (DTC) models & digital integration
DTC testing kits, which allow pet owners to collect samples at home, simplify the process and make it more convenient. This model bypasses the need for a veterinary visit, increasing accessibility and consumer engagement. By combining these at-home kits with digital platforms, companies can provide pet owners with easy-to-understand reports, personalized dietary recommendations, and access to nutritional experts. This seamless integration of technology not only enhances the user experience but also creates a scalable business model for reaching a broader customer base.
Skepticism from the scientific and veterinary communities
Concerns about the clinical relevance of microbiome data, lack of peer-reviewed validation, and inconsistent outcomes have led to cautious adoption. Some professionals question the efficacy of microbiome-based interventions without robust scientific backing. This skepticism may hinder integration into mainstream veterinary care unless supported by rigorous studies and standardized protocols. The absence of a strong scientific consensus on standardized methods and the interpretation of results can make it difficult for testing companies to gain credibility and drive widespread adoption in a market that relies heavily on professional advice.
The COVID-19 pandemic had a profound and generally positive impact on the pet gut microbiome testing market. During lockdowns, there was a significant surge in pet ownership and a new emphasis on the human-animal bond, leading to increased spending on pet health and wellness. This "pet humanization" trend accelerated as owners spent more time at home and became more attentive to their pets' well-being. The pandemic also highlighted the value of at-home health monitoring and diagnostics, which directly boosted the demand for convenient, direct-to-consumer testing kits.
The DNA sequencing kits segment is expected to be the largest during the forecast period
The DNA sequencing kits segment is expected to account for the largest market share during the forecast period attributed to the superior accuracy and comprehensive data provided by these technologies. Kits utilizing methods like 16S rRNA sequencing and shotgun metagenomics are considered the gold standard for gut microbiome analysis, offering detailed insights into the bacterial composition, diversity, and function within a pet's gut. These advanced kits are critical for both diagnostic purposes and for research, as they provide the depth of information needed for personalized treatment plans and for the development of new, targeted pet health products.
The diagnostics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the diagnostics segment is predicted to witness the highest growth rate driven by increasing demand for actionable health insights. Microbiome-based diagnostics are being used to detect gastrointestinal disorders, food sensitivities, and immune imbalances in pets. As awareness of gut health's impact on overall wellness grows, diagnostic tools are evolving to offer targeted treatment recommendations. Integration with AI-driven platforms and personalized care plans is enhancing the value proposition of microbiome diagnostics.
During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by rising pet ownership, growing disposable income, and expanding veterinary infrastructure. Countries like China, Japan, and India are witnessing increased spending on pet healthcare and wellness products. The region's tech-savvy population and rapid adoption of digital health solutions are fueling demand for microbiome testing services. Local startups and global players are investing in tailored offerings to meet diverse consumer needs.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR owing to accelerating urbanization and evolving pet care trends. The region's growing awareness of preventive health and nutrition is encouraging adoption of advanced diagnostics. Government support for biotech innovation and increasing availability of sequencing technologies are further contributing to market growth. As pet owners seek personalized and holistic care, Asia Pacific is emerging as a key hub for microbiome testing innovation and expansion.
Key players in the market
Some of the key players in Pet Gut Microbiome Testing Market include AnimalBiome, Biome9, Sun Genomics, Nom Nom, Zesty Paws, PetBiome, Microbiome Labs, Basepaws, Pooch & Mutt, Wild Earth, Fera Pet Organics, DoggyBiome, MySimplePetLab, Vetrinex Labs, Four Leaf Rover and Bernie's Perfect Poop.
In May 2025, AnimalBiome reviewed over 12,500 patients tested and support extended to 4,500+ veterinary hospitals. The update also highlighted new strategic partnerships and the launch of the AnimalBiome Veterinary Academy.
In May 2025, Sun Genomics continued expansion in microbiome research initiatives. oted for ongoing research into microbiome-targeted interventions across diverse health conditions including gastrointestinal and metabolic disorders.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.